NCT00684203View on ClinicalTrials.gov

Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)

PHASE2CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

December 1, 2006

Primary Completion Date

October 1, 2007

Study Completion Date

October 1, 2007

Conditions

AtherosclerosisMyocardial IschemiaMyocardial Infarction

Interventions

DRUG

Vorapaxar

Oral tablets; single 20-mg or 40-mg loading dose on first day followed by daily 1-mg or 2.5-mg maintenance dose for 59 days

DRUG

Placebo

Oral tablets; matching placebo for SCH 530348 loading and maintenance doses for 59 days

DRUG

Aspirin

Loading dose of 75-325 mg on Day 1, then 75-100 mg once daily for 60 days.

DRUG

Clopidogrel

100 mg two or three times daily for 60 days.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00684203 - Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016) | Biotech Hunter | Biotech Hunter